These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34419573)

  • 21. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid Polysorbate 80 Degradation by Liver Carboxylesterase in a Monoclonal Antibody Formulated Drug Substance at Early Stage Development.
    Zhang S; Xiao H; Molden R; Qiu H; Li N
    J Pharm Sci; 2020 Nov; 109(11):3300-3307. PubMed ID: 32721471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
    Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
    Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydrolytic polysorbate 20 degradation - Sensitive detection of free fatty acids in biopharmaceuticals via UPLC-QDa analytics with isolator column.
    Evers DH; Carle S; Lakatos D; Hämmerling F; Garidel P; Buske J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1174():122717. PubMed ID: 33975273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and Characterization of Polysorbate-Degrading Enzymes in a Monoclonal Antibody Formulation.
    Graf T; Tomlinson A; Yuk IH; Kufer R; Spensberger B; Falkenstein R; Shen A; Li H; Duan D; Liu W; Wohlrab S; Edelmann F; Leiss M
    J Pharm Sci; 2021 Nov; 110(11):3558-3567. PubMed ID: 34224732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
    Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
    J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Stability Study of Polysorbate 20 and Polysorbate 80 Related to Oxidative Degradation.
    Kozuch B; Weber J; Buske J; Mäder K; Garidel P; Diederichs T
    Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-lipase gene knockdown in Chinese hamster ovary cells using artificial microRNAs to reduce host cell protein mediated polysorbate degradation.
    Weiß L; Schmieder-Todtenhaupt V; Haemmerling F; Lakatos D; Schulz P; Fischer S
    Biotechnol Bioeng; 2024 Jan; 121(1):329-340. PubMed ID: 37743807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity-Based Protein Profiling Probe for the Detection of Enzymes Catalyzing Polysorbate Degradation.
    Liu GY; Nie S; Zheng X; Li N
    Anal Chem; 2022 Jun; 94(24):8625-8632. PubMed ID: 35679579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of excipients impact on polysorbate 80 degradation in biopharmaceutical formulation buffers.
    Bai L; Zhang Y; Zhang C; Lu Y; Li Z; Huang G; Meng B
    J Pharm Biomed Anal; 2023 Sep; 233():115496. PubMed ID: 37285658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
    Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stabilizing Polysorbate 20 and 80 Against Oxidative Degradation.
    Schmidt A; Koulov A; Huwyler J; Mahler HC; Jahn M
    J Pharm Sci; 2020 Jun; 109(6):1924-1932. PubMed ID: 32171713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody.
    Larson NR; Wei Y; Prajapati I; Chakraborty A; Peters B; Kalonia C; Hudak S; Choudhary S; Esfandiary R; Dhar P; Schöneich C; Middaugh CR
    J Pharm Sci; 2020 Jan; 109(1):633-639. PubMed ID: 31758949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A fast and sensitive high-throughput assay to assess polysorbate-degrading hydrolytic activity in biopharmaceuticals.
    Gupta SK; Graf T; Edelmann FT; Seelmann H; Reintinger M; Hillringhaus L; Bergmann F; Wiedmann M; Falkenstein R; Wegele H; Yuk IH; Leiss M
    Eur J Pharm Biopharm; 2023 Jun; 187():120-129. PubMed ID: 37116764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metal-Induced Fatty Acid Particle Formation Resulting from Hydrolytic Polysorbate Degradation.
    Gregoritza K; Cai SK; Siketanc M; Woehr A; Lebouc V; Kishore RSK; Nicoulin V; Bleher S; Allmendinger A
    J Pharm Sci; 2022 Mar; 111(3):743-751. PubMed ID: 34600939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of a selective marker-based quantification of polysorbate 20 in biopharmaceutical formulations using UPLC QDa detection.
    Evers DH; Schultz-Fademrecht T; Garidel P; Buske J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1157():122287. PubMed ID: 33069954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiling Active Enzymes for Polysorbate Degradation in Biotherapeutics by Activity-Based Protein Profiling.
    Li X; Chandra D; Letarte S; Adam GC; Welch J; Yang RS; Rivera S; Bodea S; Dow A; Chi A; Strulson CA; Richardson DD
    Anal Chem; 2021 Jun; 93(23):8161-8169. PubMed ID: 34032423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.